We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: immunotherapy
MedXY News
EnglishTag

immunotherapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial
Clinical UpdatesatezolizumabBCG

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

By MedXY|Jan 9, 2026

The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.

AXL: The Double-Edged Sword in Colorectal Cancer Treatment
Gastroenterologycolorectal cancerimmunotherapy

AXL: The Double-Edged Sword in Colorectal Cancer Treatment

By MedXY|Jan 9, 2026

Researchers have identified AXL expression as a critical biomarker in colorectal cancer. While it usually signals treatment resistance, a new study reveals that AXL-high tumors with KRAS mutations respond significantly better to immunothera

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial
newsfinancial toxicityimmunotherapy

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial

By MedXY|Jan 8, 2026

The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resou

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation
Gastroenterologyclinical trialimmunotherapy

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation

By MedXY|Jan 8, 2026

A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumo

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer
Gastroenterologyimmunotherapyoncology

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer

By MedXY|Jan 8, 2026

A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of

Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?
newsbreast cancerHER2-positive

Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?

By MedXY|Jan 8, 2026

The WSG-KEYRICHED-1 trial investigates a chemotherapy-free regimen for HER2-enriched early breast cancer, showing that 47% of patients achieved a pathological complete response using only immunotherapy and dual HER2 blockade.

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
newsimmunotherapyTriple-Negative Breast Cancer

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

By MedXY|Jan 8, 2026

A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminati

Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial
newsAcral Melanomaclinical trial

Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial

By MedXY|Jan 6, 2026

The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a man

Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial
GastroenterologyimmunotherapyTIGIT

Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial

By MedXY|Jan 6, 2026

The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced o

Dual Checkpoint Inhibition: Tiragolumab and Atezolizumab Set New Survival Benchmarks in Advanced Esophageal Squamous Cell Carcinoma
GastroenterologyEsophageal Cancerimmunotherapy

Dual Checkpoint Inhibition: Tiragolumab and Atezolizumab Set New Survival Benchmarks in Advanced Esophageal Squamous Cell Carcinoma

By MedXY|Jan 6, 2026

The Phase 3 SKYSCRAPER-08 trial demonstrates that adding the anti-TIGIT tiragolumab and anti-PD-L1 atezolizumab to chemotherapy significantly extends overall survival and progression-free survival in patients with treatment-naive, unresecta

Immunotherapy Challenges in Metastatic Castration-Resistant Prostate Cancer: An In-Depth Analysis of the CheckMate 7DX Phase 3 Trial
Clinical Updatesclinical trialDocetaxel

Immunotherapy Challenges in Metastatic Castration-Resistant Prostate Cancer: An In-Depth Analysis of the CheckMate 7DX Phase 3 Trial

By MedXY|Jan 5, 2026

CheckMate 7DX demonstrates that adding nivolumab to docetaxel fails to improve survival outcomes in ARPI-pretreated, chemotherapy-naive mCRPC, while significantly increasing toxicity and treatment-related mortality.

“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS
Allergy & ImmunologyALSimmunotherapy

“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS

By MedXY|Dec 31, 2025

A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Diabetes & Endocrinologydiabetesimmunotherapy

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

By MedXY|Dec 29, 2025

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immu

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC
newsHNSCCimmunotherapy

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC

By MedXY|Dec 23, 2025

A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate

Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome
AICytokine release syndromeGiám sát Bệnh nhân Từ xa

Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome

By MedXY|Dec 21, 2025

This article explores a landmark mixed-methods study establishing a digital biomarker ontology for the early detection of Cytokine Release Syndrome (CRS). By identifying core physiological markers, researchers aim to transform immunotherapy

Hematology-Oncologybispecific antibodyimmunotherapy

Comprehensive Summary of Talquetamab Monotherapy and Combination Therapy in Relapsed or Refractory Multiple Myeloma

By MedXY|Dec 19, 2025

Talquetamab, alone or combined with teclistamab, shows promising efficacy in treating relapsed/refractory multiple myeloma, including extramedullary disease, though high-grade adverse events are common but manageable.

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
Hematology-OncologyBispecific Antibodiesdaratumumab

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

By MedXY|Dec 18, 2025

The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high ra

Atezolizumab–Bevacizumab Provides the Best Balance of Survival and Quality of Life in First‑Line Advanced Hepatocellular Carcinoma
newshepatocellular carcinomaimmunotherapy

Atezolizumab–Bevacizumab Provides the Best Balance of Survival and Quality of Life in First‑Line Advanced Hepatocellular Carcinoma

By MedXY|Dec 14, 2025

A Bayesian network meta-analysis integrating health‑related quality of life and overall survival across first‑line trials in advanced hepatocellular carcinoma shows atezolizumab plus bevacizumab provides the most favorable combined patient‑

Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know
Hematology-Oncologydịch vụ chăm sóc cuối đờihealth services use

Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know

By MedXY|Dec 13, 2025

In a population-based Ontario study, use of systemic anticancer therapy (SACT) in the last 30 days of life increased—driven by immunotherapy—and was associated with higher emergency visits, hospitalizations, ICU admissions, and hospital dea

Rising Use of Novel Systemic Anticancer Therapies at End of Life Is Associated With More Hospital-Based Care
Hematology-Oncologydịch vụ chăm sóc cuối đờihealth services use

Rising Use of Novel Systemic Anticancer Therapies at End of Life Is Associated With More Hospital-Based Care

By MedXY|Dec 12, 2025

Use of systemic anticancer therapy in the last 30 days of life rose from 2015–2020, mainly due to immunotherapy; any SACT was linked to more than twofold higher odds of multiple ED visits, hospitalizations, ICU admission, and in-hospital de

Prev
5 / 9
1…34567…9
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities